Ashland expands bioresorbable development site in Ireland

Published: 31-Aug-2022

The bioresorbable polymers are used to deliver improved treatment solutions for many chronic diseases

American chemical company Ashland has announced an expansion of its Viatel bioresorbable polymer manufacturing and research development site at the National Science Park in Mullingar, Ireland.

"Doubling both our footprint, which includes manufacturing and laboratory space, and the headcount of this facility allows us to deliver cutting-edge polymer chemistry by increasing scope, capacity, and capabilities, and to respond to growing customer needs with greater speed," said Seán McMahon, Ph.D., Business Manager, Viatel bioresorbable polymers, Ashland.

Viatel bioresorbable polymers are used to deliver improved treatment solutions for many chronic diseases. These polymers are the innovative building blocks in long-acting release formulations, bioresorbable medical devices and tissue engineering scaffolds.

The facility expansion further establishes Ashland as an attractive employer in Ireland

"Expansion of the facility in Ireland showcases our commitment to innovation in the long acting injectables space," said Ashok Kalyana, Senior VP and General Manager of Life Sciences for Ashland. "We are actively helping our customers solve for performance attributes that will ultimately allow patients to take less medicine, fewer times."

Ashland supplies more than 70 good manufacturing practice (GMP) grades of lactide/glycolide/caprolactone copolymers within its growing Viatel portfolio and offers custom-made polymer production to serve changing customer requirements.

Like this story? Subscribe to Manufacturing Chemist magazine for the latest news, updates and expert-written articles from the global pharmaceutical and biopharma sectors. For more information click here.

"The facility expansion further establishes Ashland as an attractive employer in Ireland," said Brandt Giffin, Senior Director of Marketing and New Business Development for Life Sciences at Ashland. "Our Pharma business is at the heart of our specialty focus. This expansion allows us to continue to build our poly lactic- co-glycolic acid (PLGA) business that enables and supports new market trends."

The capital expansion program commenced in June 2022 and is expected to finish in 2024.

You may also like